Cosmetic peptide comparison: GHK-Cu vs AHK-Cu vs Snap-8 vs Matrixyl

Cosmetic OEM brands and med-aesthetic formulators routinely make procurement decisions across the four most-procured cosmetic peptides: GHK-Cu, AHK-Cu, Snap-8, and Matrixyl. Each occupies a distinct mechanistic and application niche, and the formulation considerations differ meaningfully between them.

This article compares the four peptides on the dimensions that drive procurement decisions.

At a glance

Mechanism distinctions

GHK-Cu acts through copper-dependent signaling pathways on dermal fibroblasts. The Cu(II) coordination drives multiple downstream effects including collagen synthesis upregulation, elastin synthesis, and antioxidant signaling. The peptide itself is essentially a copper-delivery vehicle, without intact Cu²⁺ coordination (color check: deep blue), the molecule loses most of its biological activity.

AHK-Cu uses the same copper-mediated signaling framework but with a single-residue substitution (Ala instead of Gly at the N-terminus). The substitution shifts tissue-selectivity toward follicular biology, AHK-Cu is preferentially used in hair-regrowth and scalp-tissue applications, while GHK-Cu dominates dermal-tissue applications. The two are often combined in scalp-plus-skin formulations.

Snap-8 is mechanistically distinct from both copper peptides. The peptide is a SNAP-25 mimetic designed to competitively inhibit SNAP-25 incorporation into the SNARE complex, modulating neurotransmitter release at the neuromuscular junction. The cosmetic positioning is in expression-line serums, the mechanism premise is reducing the muscle-contraction signal that creates dynamic wrinkles.

Matrixyl is also mechanistically distinct. The palmitoyl-KTTKS molecule delivers the KTTKS pentapeptide (a fragment of human procollagen type I) across the stratum corneum to dermal fibroblasts, where the pentapeptide signals collagen synthesis upregulation. The palmitoyl group is a delivery vehicle, not a pharmacophore.

Use-level and cost considerations

The four peptides have substantially different per-mg pricing and therefore different finished-product cost contributions at typical use levels:

• Matrixyl at 5% use level in a finished serum represents about $5-15 of peptide cost per 30 mL bottle (depending on bulk procurement scale)
• Snap-8 at 7% use level: about $2-8 per 30 mL bottle
• GHK-Cu at 1% use level: about $0.50-2 per 30 mL bottle (lowest per-finished-unit because the use level is much lower)
• AHK-Cu at 0.5% use level: about $0.30-1.50 per 30 mL bottle

For premium-positioned multi-active products, brands typically combine GHK-Cu + Matrixyl + Snap-8 in a single formulation; the peptide-cost contribution to finished product COGS at typical use levels is roughly $7-25 per 30 mL bottle. Retail pricing for such products typically lands $80-250, so peptide-active cost is a meaningful but not dominant share of finished-product economics.

Formulation compatibility matrix

Within the same finished product:

• GHK-Cu + Matrixyl: Compatible. GHK-Cu handles dermal repair / Cu-signaling; Matrixyl handles collagen stimulation. Use level: 0.5-1.0% GHK-Cu + 3-5% Matrixyl.
• GHK-Cu + Snap-8: Compatible. Different mechanisms (Cu-signaling vs SNAP-25-mimetic). Use level: 0.5-1.0% GHK-Cu + 5-7% Snap-8.
• GHK-Cu + AHK-Cu: Compatible. Two copper peptides with different tissue-selectivity (dermal vs follicular). Typically used in finished products targeting both skin and scalp.
• Matrixyl + Snap-8: Compatible. Different mechanisms. Use level: 3-5% Matrixyl + 5-7% Snap-8.
• All four in one product: Compatible at moderate use levels (premium multi-active formulations).

Incompatible combinations within the same phase:

• Either copper peptide + EDTA / strong chelators: Strips copper away from the peptide, destroying activity. Use chelator-free water throughout.
• Either copper peptide + high-strength ascorbic acid: Reduces Cu(II) to Cu(I), breaking the active complex. Vitamin C should be in a separate phase or product.
• Matrixyl + strongly alkaline systems (pH >8): Hydrolyzes the palmitoyl-amide linkage, releasing free palmitic acid + free KTTKS (which loses topical-penetration ability).

INCI naming and regulatory considerations

For EU CPNP notification and most international cosmetic-regulatory frameworks, INCI names must appear in the finished-product ingredient list:

• GHK-Cu: Copper Tripeptide-1
• AHK-Cu: Custom INCI required; confirm with Vialdyne regulatory team
• Snap-8: Acetyl Octapeptide-3
• Matrixyl: Palmitoyl Pentapeptide-4

Vialdyne's regulatory team supports the documentation chain for finished-product notification in EU CPNP, FDA cosmetic-monograph workflows, China NMPA registries, and equivalent frameworks in other markets. Specify the destination market at quote stage so the documentation scope matches the launch regulatory pathway.

How to choose

Single-active anti-aging serum (entry-level): Matrixyl (collagen-stimulation) at 5% use level. Most established mechanism, well-recognized INCI.

Single-active anti-aging serum (clinic-positioning): GHK-Cu at 1% use level. Distinctive blue color provides visual differentiation and signals the active.

Dual-active anti-aging serum: GHK-Cu (0.5-1.0%) + Matrixyl (3-5%). Mechanistically complementary; premium positioning.

Triple-active anti-aging serum (premium): GHK-Cu (1.0%) + Matrixyl (5%) + Snap-8 (5-7%). Covers dermal repair + collagen stimulation + expression-line claim. Premium retail positioning.

Hair-regrowth scalp serum: AHK-Cu at 0.5-1.0%. Sometimes combined with GHK-Cu (0.3%) for dermal-scalp combination claims.

Combined skin + scalp regimen (multi-product): Develop two finished products in parallel, anti-aging serum with GHK-Cu + Matrixyl + Snap-8, plus scalp serum with AHK-Cu. The two products share supply-chain economics and brand positioning.

For the broader cosmetic OEM workflow including formulation development, stability testing, and regulatory support, see our GHK-Cu formulation guide and med-spa buyer's playbook.